Macrophage activation of lymphoma-bearing mice by liposome-mediated intraperitoneal IL-2 and IL-6 gene therapy.
OBJECTIVE
To investigate the antitumor mechanism of interleukin-2 (IL-2) and interleukin-6 (IL-6) gene therapy.


METHODS
Liposome encapsulated IL-2 DNA and IL-6 DNA were intraperitoneally (i.p.) injected into mouse lymphoma cell line (EL-4) lymphoma-bearing mice. Macrophage function (M phi) from the mice was assessed.


RESULTS
Cytotoxicity, major histocompatibility (MHC) II expression and IL-1 and TNF secretion of the macrophages all augmented after i.p. injection of liposome encapsulated IL-2 DNA or IL-6 DNA. More efficient activation of macrophages was observed in mice treated with liposome encapsulated IL-2 DNA than IL-6 DNA. IL-2 gene therapy combined with IL-6 gene therapy showed the maximal activation of macrophages in the lymphoma-bearing mice.


CONCLUSIONS
IL-2 and IL-6 gene therapy can relieve the suppression of macrophages of the lymphoma-bearing mice, and efficiently activate the antitumor immune responses.
Wang
Q
Q
Department of Immunology, Second Military Medical University, Shanghai 200433, China.
Cao
X
X
Wang
J
J
Zhang
W
W
Tao
Q
Q
Ye
T
T
D000818:Animals; D015316:Genetic Therapy; D007274:Injections, Intraperitoneal; D007376:Interleukin-2 / Q000235:genetics* / Q000378:metabolism; D015850:Interleukin-6 / Q000235:genetics* / Q000378:metabolism; D008081:Liposomes; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D008262:Macrophage Activation; D017737:Macrophages, Peritoneal / Q000276:immunology; D051379:Mice; D014407:Tumor Cells, Cultured
D007376:Interleukin-2; D015850:Interleukin-6; D008081:Liposomes